Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared ...
Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the ...
Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or ...
A coordinated national effort is emerging to bring alternatives to animal testing into routine preclinical use, backed by a ...
The record-setting government shutdown was just the latest blow to the U.S. biopharma industry. When science funding becomes ...
Richard Pazdur, the new director of the Center for Drug Evaluation and Research, raised concerns amid the rollout of several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback